Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial

The study analyzed the effects of continued ritlecitinib treatment on patients with alopecia areata over a 48-week period as part of the ALLEGRO phase 2b/3 trial. It was found that hair regrowth was sustained through week 48 in patients who had shown a response by week 24. Additionally, up to one-third of patients who did not initially meet the target efficacy at week 24 eventually achieved a response with ongoing treatment. This suggests that continued ritlecitinib treatment can be beneficial for sustained hair regrowth in alopecia areata patients, even for those who do not respond early in the treatment process.